The Nosology Committee of the International Skeletal Dysplasia Society currently recognizes 461 skeletal disorders and 437 genes that are associated with 425 of these disorders (Mortier et al., 2019). As these associations are identified, methods such as Next Generation Sequencing and genetic modification of model organisms are used to parse out the underlying genetic mechanisms of skeletal diseases. CRISPR-modified mouse and zebrafish models have been used to understand the mechanisms for skeletal diseases such as sclerosteosis, osteoporosis, and osteogenesis imperfecta, as well as more rare variations of these disorders (Garg et al., 2022;Kaya et al., 2022;Kwon et al., 2019). Using model organisms to understand the genetic mechanism of these disorders presents opportunities to develop and test potential treatments (Kague & Karasik, 2022). However, for these models to be useful, the homologous genes in model organisms must present observable phenotypes that parallel the symptoms of human diseases. Current best practices use measures such as tissue mineral density and bone thickness to identify phenotypes that are common between model